Dermira Inc. shares were halted in premarket trade Monday on news that the company’s acne drug failed to meet the co-primary endpoints of two phase 3 clinical trials. The company expects to discontinue development of the therapy, olumacostat glasaretil, which was intended for moderate-to-severe acne vulgaris, also known as simply acne. Dermira shares dropped 4.7% in premarket trade prior to the halt. Shares have risen 3.9% over the last three months to $25.16, compared with a 2.4% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News